BridgeBio Pharma has moved oral infigratinib into the final stage of U.S. regulatory review after the FDA accepted its New Drug Application and granted Priority Review for children with achondroplasia. The agency has assigned a February 4, 2027 target action date, setting up a potential approval of the first oral pharmacologic treatment for the genetic skeletal condition. The application is supported by the randomized Phase 3 PROPEL 3 study, in which once-daily infigratinib significantly increased annualized height velocity compared with placebo while maintaining a safety profile similar to control.
The regulatory milestone comes as treatment options for achondroplasia have expanded considerably. Vosoritide and navepegritide are already FDA approved to increase linear growth in children with open growth plates, but both require subcutaneous administration. Infigratinib would introduce an oral treatment that directly inhibits the overactive FGFR3 signaling responsible for achondroplasia, creating a distinct mechanistic and dosing alternative if the FDA concludes that the Phase 3 benefit-risk profile supports approval.
PROPEL 3 showed a significant increase in annualized height velocity after 52 weeks
PROPEL 3 was a multinational, double-blind, placebo-controlled Phase 3 study enrolling children with achondroplasia between three and 17 years of age. A total of 114 participants were randomized in a 2:1 ratio to receive oral infigratinib at 0.25 mg/kg once daily or placebo for 52 weeks.
The primary endpoint was change from baseline in annualized height velocity at Week 52. The least-squares mean treatment difference between infigratinib and placebo was 1.74 centimeters per year, with a 95% confidence interval of 1.31 to 2.17 centimeters and a p-value below 0.001. BridgeBio Pharma separately reported a raw mean treatment difference of 2.10 centimeters per year.
Height Z-score also improved significantly. The difference between groups was 0.32 standard deviations, with a 96% confidence interval of 0.23 to 0.41 and a p-value below 0.001. The findings indicate that the additional growth seen with infigratinib was sufficiently consistent across the randomized population to satisfy both the primary endpoint and an important secondary measure.
BridgeBio Pharma has described the magnitude of the annualized height-velocity effect as the largest reported in a Phase 3 achondroplasia study. That characterization is based on cross-trial comparisons and should therefore be interpreted cautiously because studies of different therapies vary in age distributions, statistical methods and control populations. The more defensible conclusion is that PROPEL 3 demonstrated a robust placebo-controlled increase in linear growth with oral infigratinib.
Body proportionality findings provide an additional signal but require more nuanced interpretation
Achondroplasia affects more than final height. Overactive FGFR3 signaling disrupts normal growth-plate development and produces disproportionate skeletal growth, with relatively shorter limbs compared with the trunk. Patients can also develop spinal stenosis, sleep apnea, middle-ear disease and other neurological, musculoskeletal and cardiorespiratory complications.
BridgeBio Pharma highlighted a prespecified exploratory analysis showing statistically significant improvement in body proportionality among children younger than eight years, a group representing more than half of the PROPEL 3 population. The company said this was the first randomized Phase 3 achondroplasia study to show a significant placebo-controlled improvement in proportionality within that subgroup.
The full-population result requires greater caution. In the peer-reviewed PROPEL 3 publication, the difference between infigratinib and placebo in upper-to-lower body segment ratio was -0.02, with a 96% confidence interval extending from -0.06 to 0.01. Because that interval crossed zero, the overall proportionality analysis did not demonstrate the same clear statistical separation seen for annualized height velocity and height Z-score.
BridgeBio Pharma has also reported exploratory trends involving arm span, sleep apnea and otitis media. These measures could become clinically meaningful if longer follow-up confirms that modifying FGFR3 signaling improves broader medical complications associated with achondroplasia, but the current regulatory package is most firmly supported by the prospective growth endpoints.
Safety remained similar to placebo with no treatment-related serious adverse events
The Phase 3 safety dataset did not identify a major imbalance between treatment groups. Adverse events occurred in 96% of children receiving infigratinib and 95% receiving placebo, while serious adverse events were reported in 5% and 3%, respectively. Investigators did not attribute any serious adverse event or any treatment discontinuation to infigratinib or placebo.
That profile is relevant because infigratinib is an FGFR1-3 tyrosine kinase inhibitor, a mechanism previously explored in oncology at substantially different therapeutic settings and exposures. Long-term pediatric use requires confidence that chronic pathway inhibition does not introduce developmental or metabolic effects that outweigh the growth benefit.
BridgeBio Pharma will therefore need continued safety surveillance beyond the 52-week pivotal period. Achondroplasia treatment generally begins while growth plates remain open and may continue for years, making longer-term effects on skeletal development, mineral metabolism and other organ systems important to the eventual benefit-risk assessment.
The current randomized results are nevertheless reassuring because the rate of overall adverse events was comparable with placebo and there were no treatment-related serious adverse events or discontinuations during the pivotal period.
Oral infigratinib would enter a market that already includes daily and weekly injectable treatments
The competitive environment has changed substantially since infigratinib entered development. Voxzogo, or vosoritide, became the first FDA-approved pharmacologic treatment to increase linear growth in children with achondroplasia and is now authorized across pediatric patients with open growth plates.
Ascendis Pharma added another option when the FDA approved Yuviwel, or navepegritide, for children two years and older with open epiphyses. Yuviwel is administered once weekly and became commercially available in the United States in April 2026.
Both approved medicines work through the C-type natriuretic peptide pathway and require injections. Infigratinib instead directly inhibits FGFR3, the receptor whose activating mutation drives achondroplasia, and would be administered orally once daily.
That difference could matter for families weighing convenience, administration burden and treatment preferences over many years. An oral option eliminates injections but requires daily adherence, while Yuviwel requires only one injection each week. Treatment selection would therefore involve more than comparing annualized growth velocity alone.
The current approved medicines also illustrate an important regulatory point. Both Voxzogo and Yuviwel received accelerated approval based on improvement in linear growth, with continued approval dependent on confirmatory evidence concerning longer-term clinical benefit, including final adult height.
Infigratinib targets the causal FGFR3 pathway rather than stimulating a compensatory growth signal
Achondroplasia is caused by activating variants in FGFR3. The resulting excess receptor signaling suppresses growth-plate chondrocyte proliferation and differentiation, producing impaired endochondral bone growth and the characteristic skeletal phenotype.
Infigratinib is a small-molecule inhibitor of FGFR1, FGFR2 and FGFR3. At the low dose developed for achondroplasia, BridgeBio Pharma intends the therapy to reduce pathological FGFR3 signaling and thereby restore a more normal balance within the growth plate.
That approach differs from the approved CNP-based therapies, which act downstream to counter FGFR3 signaling rather than directly inhibiting the receptor. Whether the mechanistic difference eventually produces meaningful distinctions in final height, proportionality or medical complications remains unknown and cannot be determined from separate Phase 3 trials. The FDA previously granted infigratinib Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for achondroplasia. BridgeBio Pharma is also preparing a European marketing application and expects to submit it during the fourth quarter.
February FDA decision could create a third pharmacologic option and the first oral treatment
BridgeBio Pharma estimates that approximately 55,000 people in the United States and European Union live with achondroplasia, including up to 10,000 children and adolescents who still have open growth plates. The potential addressable treatment population is therefore relatively concentrated but increasingly competitive following the arrival of multiple disease-targeted medicines.
The company is also studying infigratinib beyond achondroplasia. Development programs include hypochondroplasia, another skeletal dysplasia involving FGFR3 signaling, which could eventually broaden the clinical role of the molecule if ongoing trials are successful.
For the immediate program, the February 4 FDA decision will determine whether BridgeBio Pharma can add an oral therapy to a treatment landscape currently dominated by injectable medicines. PROPEL 3 provides statistically strong evidence that infigratinib increases growth velocity over one year, while the overall safety profile remained comparable with placebo.
Questions beyond linear growth will require longer observation. The younger-child proportionality signal, arm-span findings and trends in sleep apnea and ear infections are intriguing, but they are less definitive than the pivotal growth results and should not yet be interpreted as proof that infigratinib reduces the broader medical burden of achondroplasia.
If approved, the clinical discussion will quickly shift from whether infigratinib works to how its efficacy, oral administration, long-term safety and broader skeletal effects compare with two already available treatments. The FDA Priority Review moves that competitive question considerably closer.
